Subscribe
jeng-niamwhan-shutterstock-com
JENG_NIAMWHAN / Shutterstock.com
20 May 2015Americas

Gilead faces fresh Sovaldi challenge

Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi (sofosbuvir) in certain Asian, Latin American and European countries.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
SIPO rejects Gilead’s Sovaldi patent application
23 June 2015   China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Asia-Pacific
SIPO rejects Gilead’s Sovaldi patent application
23 June 2015   China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More on this story

Asia-Pacific
SIPO rejects Gilead’s Sovaldi patent application
23 June 2015   China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent